Literature DB >> 9566425

Olanzapine can worsen parkinsonism.

F J Jiménez-Jiménez1, A Tallón-Barranco, M Ortí-Pareja, M Zurdo, J Porta, J A Molina.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9566425     DOI： 10.1212/wnl.50.4.1183-a

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  9 in total

Review 1.  Antipsychotic medications and the elderly: effects on cognition and implications for use.

Authors:  M J Byerly; M T Weber; D L Brooks; L R Snow; M A Worley; E Lescouflair
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

2.  The effect of quetiapine in psychotic Parkinsonian patients with and without dementia. An open-labeled study utilizing a structured interview.

Authors:  T Prohorov; C Klein; A Miniovitz; E Dobronevsky; J M Rabey
Journal:  J Neurol       Date:  2005-08-17       Impact factor: 4.849

Review 3.  Parkinson's disease: the treatment of drug-induced hallucinations and psychosis.

Authors:  E S Molho; S A Factor
Journal:  Curr Neurol Neurosci Rep       Date:  2001-07       Impact factor: 5.081

Review 4.  Treating Hallucinations and Delusions Associated With Parkinson's Disease Psychosis.

Authors:  Shyam C Panchal; William G Ondo
Journal:  Curr Psychiatry Rep       Date:  2018-01-27       Impact factor: 5.285

5.  Novel Antipsychotics in the Treatment of Behavioral Disturbances and Psychoses Associated With Neurodegenerative Disorders.

Authors:  Prakash S. Masand
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2000-06

Review 6.  Treatment of psychosis in Parkinson's disease: safety considerations.

Authors:  Hubert H Fernandez; Martha E Trieschmann; Joseph H Friedman
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

7.  Treatment of the special patient with schizophrenia.

Authors:  R R Conley; D L Kelly
Journal:  Dialogues Clin Neurosci       Date:  2001-06       Impact factor: 5.986

8.  A fixed-dose randomized controlled trial of olanzapine for psychosis in Parkinson disease.

Authors:  Michelle J Nichols; Johanna M Hartlein; Meredith Ga Eicken; Brad A Racette; Kevin J Black
Journal:  F1000Res       Date:  2013-07-09

Review 9.  Current and Future Neuropharmacological Options for the Treatment of Essential Tremor.

Authors:  Hortensia Alonso-Navarro; Elena García-Martín; José A G Agúndez; Félix J Jiménez-Jiménez
Journal:  Curr Neuropharmacol       Date:  2020       Impact factor: 7.363
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.